Rapid Prostate Cancer Noninvasive Biomarker Screening Using Segmented Flow Mass Spectrometry-Based Untargeted Metabolomics

作     者：Pinto, Frederico G. Mahmud, Iqbal Harmon, Taylor A. Rubio, Vanessa Y. Garrett, Timothy J. 

作者机构：Univ Florida Dept Pathol Immunol & Lab Med Clin & Translat Sci Inst Gainesville FL 32610 USA Univ Florida Southeast Ctr Integrated Metabol Clin & Translat Sci Inst Gainesville FL 32610 USA Univ Fed Vicosa Inst Ciencias Exatas & Tecnol BR-36570900 Vicosa MG Brazil Univ Florida Dept Chem Gainesville FL 32603 USA 

出 版 物：《JOURNAL OF PROTEOME RESEARCH》 (蛋白质组研究杂志)

年 卷 期：2020年第19卷第5期

页      面：2080-2091页

核心收录：

学科分类：0710[理学-生物学] 071010[理学-生物化学与分子生物学] 081704[工学-应用化学] 07[理学] 08[工学] 0817[工学-化学工程与技术] 

基　　金：National Institutes of Health [U24DK097209] Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brazil (CAPES) [001, 88881.172523/2018-01] 

主　　题：metabolomics segmented flow high-resolution mass spectrometry prostate cancer urine liquid biopsy noninvasive biomarker 

摘      要：Spectrometric methods with rapid biomarker detection capacity through untargeted metabolomics are becoming essential in the clinical cancer research. Liquid chromatography-mass spectrometry (LC-MS) is a rapidly developing metabolomic-based biomarker technique due to its high sensitivity, reproducibility, and separation efficiency. However, its translation to clinical diagnostics is often limited due to long data acquisition times (similar to 20 min/sample) and laborious sample extraction procedures when employed for large-scale metabolomics studies. Here, we developed a segmented flow approach coupled with high-resolution mass spectrometry (SF-HRMS) for untargeted metabolomics, which has the capability to acquire data in less than 1.5 min/sample with robustness and reproducibility relative to LC-HRMS. The SF-HRMS results demonstrate the capability for screening metabolite-based urinary biomarkers associated with prostate cancer (PCa). The study shows that SF-HRMS-based global metabolomics has the potential to evolve into a rapid biomarker screening tool for clinical research.